Year 2017 / Volume 109 / Number 8
Original
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients

552-558

DOI: 10.17235/reed.2017.4809/2016

Blas José Gómez Rodríguez, Luisa Castro Laria, Federico Argüelles Arias, Cristina Castro Márquez, Ángel Caunedo Álvarez, Manuel Romero Gómez,

Abstract
Objective: To evaluate the efficacy and safety of a quadruple regimen (BMTO) of the “3-in-1 capsule” (containing bismuth subcitrate potassium, metronidazole and tetracycline) plus omeprazole in naïve and previously treated patients diagnosed with Helicobacter pylori (H. pylori) infection in the clinical setting in Seville (Spain). Methods: This is a prospective study carried out on consecutive patients with a confirmed H. pylori infection and upper gastrointestinal symptoms. After providing their informed consent, the patients were treated for ten days with a 3-in-1 capsule containing bismuth subcitrate potassium (140 mg), metronidazole (125 mg) and tetracycline (125 mg: Pylera®), three capsules four times daily, plus omeprazole (20 or 40 mg) twice daily. Eradication of infection was determined by a negative urea breath test at least 28 days after the end of treatment. Results: A total of 58 consecutive patients were enrolled into this study, two of whom withdrew early due to vomiting on days three and five, respectively. In this cohort, 17 patients (29.3%) had a prior history of medication to treat H. pylori. In the intent-to-treat population, eradication was achieved in 97.6% (40/41) and 82.4% (14/17) of cases in patients treated with BMTO as a first-line or rescue therapy, respectively. At least one adverse event was reported by 28 (48%) patients, mostly mild effects (86%). Conclusion: A ten day treatment with BMTO is an effective and safe strategy to combat confirmed H. pylori infection in patients.
Share Button
New comment
Comments

01/02/2023 7:47:44
striplife.ru


08/01/2019 19:10:01
Yo hice 8 terapias incluido pylera y no lo eradique


References
1. Calvet X, Ramírez Lázaro MJ, Lehours P, et al. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013; 18 Suppl 1: 5-11.
2. Mentis A, Lehours P, Mégraud F. Epidemiology and Diagnosis of Helicobacter pylori infection. Helicobacter. 2015 Sep;20 Suppl 1:1-7.
3. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001 Sep 13;345(11):784-9.
4. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597–604.
5. Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015 Apr;41(8):768-75.
6. Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016 Jan 16;4(1):5-19.
7. Malfertheiner P, Megraud F, O’Morain C. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81.
8. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808–25.
9. Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J 2013; 54: 1-4.
10. Megraud F, Coenen S, Versporten A, et al; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013 Jan;62(1):34-42.
11. Lv ZF, Wang FC, Zheng HL, et al. Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol. 2015 Feb 28;21(8):2522-33.
12. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000 Dec;95(12):3393-8.
13. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004 Jul 1;20(1):99-107.
14. Seddik H, Ahid S, El Adioui T, et al. Sequential therapy versus standard tripledrug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 2013; 69: 1709-1715.
15. Gisbert JP, Molina-Infante J, Amador J, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 2016 Jun 21. pii: S0210-5705(16)30058-9.
16. Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016 Oct 5. pii: gutjnl-2016-312288.
17. Molina-Infante J, Gisbert JP. Actualización de la eficacia de la terapia triple para la infección por Helicobacter pylori y de la resistencia a claritromicina en España (2007-2012). Gastroenterol Hepatol. 2013 Jun-Jul;36(6):375-81.
18. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 2008; 68: 725–36.
19. Dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review. World J Gastroenterol 2015; 21: 139-154.
20. O'Morain C, Borody T, Farley A, et al; International multicentre study. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003 Feb;17(3):415-20.
21. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003 Mar; 98(3): 562-7.
22. Saleem A, Qasim A, O'Connor HJ, et al. Pylera for the eradication of Helicobacter pylori infection. Expert Rev Anti Infect Ther. 2009 Sep;7(7):793-9.
23. Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010 Jun;15(3):233-8.
24. Malfertheiner P, Bazzoli F, Delchier JC, et al; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13.
25. Uygun A, Ozel AM, Yildiz O, et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 2008; 23:42–5.
26. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013 Jul;11(7):802-7. e1.
27. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014 Jul;40(2):171-7.
28. Hsu PI, Chen WC, Tsay FW, et al; Taiwan Acid-Related Disease (TARD) Study Group. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter. 2014 Feb;19(1):74-9.
29. Gisbert JP, Perez-Aisa A, Rodrigo L, et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci 2014; 59:383–9.
30. Malfertheiner P. Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nat Rev Gastroenterol Hepatol 2010; 7: 538–9.
31. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014; 11:628–38.
32. Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):517-24.
Related articles

Special Article

V Spanish Consensus Conference on Helicobacter pylori infection treatment

DOI: 10.17235/reed.2021.8358/2021

Letter to the Editor

A question about dyspeptic patients analyzed using psychometric scores

DOI: 10.17235/reed.2017.5401/2017

Letter to the Editor

Acute psychotic episode secondary to Helicobacter pylori eradication treatment

DOI: 10.17235/reed.2017.4482/2016

Citation tools
Gómez Rodríguez B, Castro Laria L, Argüelles Arias F, Castro Márquez C, Caunedo Álvarez Á, Romero Gómez M, et all. A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. 4809/2016


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1171 visits.
This article has been downloaded 416 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 22/12/2016

Accepted: 08/03/2017

Online First: 15/06/2017

Published: 31/07/2017

Article revision time: 69 days

Article Online First time: 175 days

Article editing time: 221 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology